ResearcherUniversity of PittsburghNo recent work listed
Leonidas E. Bantis
Matched on ORCID iD 0000-0002-2364-2562; OpenAlex author ID A5034092815. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 35
2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 1 paper
Papers 6
- On optimal biomarker cutoffs accounting for misclassification costs in diagnostic trilemmas with applications to pancreatic cancer. Co-author DOI 10.1002/sim.9432↗
- CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. Co-author DOI 10.1200/po.19.00330↗
- Survival Outcomes of Pancreatic Intraepithelial Neoplasm (PanIN) versus Intraductal Papillary Mucinous Neoplasm (IPMN) Associated Pancreatic Adenocarcinoma. First author DOI 10.3390/jcm9103102↗
- Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Co-author DOI 10.1038/s41467-018-08109-6↗
- A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. First author DOI 10.1093/jnci/djy126↗
- Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. First author DOI 10.1093/jnci/djw266↗
Closest collaborators
The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- John Tsimikas · 1 shared paper, 2022 · strength 0.33
- Michela Capello · 4 shared papers, 2017–2020 · strength 0.27
- Paper CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diab… DOI 10.1200/po.19.00330↗
- Paper A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. DOI 10.1093/jnci/djy126↗
- Paper Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytoto… DOI 10.1038/s41467-018-08109-6↗
- Samir Hanash · 4 shared papers, 2017–2020 · strength 0.27
- Paper CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diab… DOI 10.1200/po.19.00330↗
- Paper A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. DOI 10.1093/jnci/djy126↗
- Paper Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytoto… DOI 10.1038/s41467-018-08109-6↗
- Anirban Maitra · 4 shared papers, 2017–2020 · strength 0.27
- Paper CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diab… DOI 10.1200/po.19.00330↗
- Paper A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. DOI 10.1093/jnci/djy126↗
- Paper Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytoto… DOI 10.1038/s41467-018-08109-6↗
- Jody V. Vykoukal · 3 shared papers, 2019–2020 · strength 0.22
- Paper CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diab… DOI 10.1200/po.19.00330↗
- Paper A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. DOI 10.1093/jnci/djy126↗
- Paper Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytoto… DOI 10.1038/s41467-018-08109-6↗
- Ziding Feng · 3 shared papers, 2019–2020 · strength 0.22
- Paper CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diab… DOI 10.1200/po.19.00330↗
- Paper A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. DOI 10.1093/jnci/djy126↗
- Paper Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytoto… DOI 10.1038/s41467-018-08109-6↗
- Matthew H. G. Katz · 3 shared papers, 2017–2020 · strength 0.20
- Paper CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diab… DOI 10.1200/po.19.00330↗
- Paper Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytoto… DOI 10.1038/s41467-018-08109-6↗
- Paper Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. DOI 10.1093/jnci/djw266↗
- Randall E. Brand · 3 shared papers, 2017–2019 · strength 0.19
- Paper A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. DOI 10.1093/jnci/djy126↗
- Paper Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytoto… DOI 10.1038/s41467-018-08109-6↗
- Paper Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. DOI 10.1093/jnci/djw266↗
- Johannes Francois Fahrmann · 2 shared papers, 2019–2020 · strength 0.15
- Vladimír Janout · 2 shared papers, 2017–2019 · strength 0.12
- Ghislaine Scélo · 2 shared papers, 2017–2019 · strength 0.12
- Matthew A. Firpo · 2 shared papers, 2017–2019 · strength 0.12
- Sean J. Mulvihill · 2 shared papers, 2017–2019 · strength 0.12
- Prasad R. Dandawate · 1 shared paper, 2020 · strength 0.12
- Timothy McGinnis · 1 shared paper, 2020 · strength 0.12
- Anup Kasi · 1 shared paper, 2020 · strength 0.12
- Ravi Kumar Paluri · 1 shared paper, 2020 · strength 0.12
- Mayrim V. Rios Perez · 1 shared paper, 2020 · strength 0.08
- Ehsan Irajizad · 1 shared paper, 2020 · strength 0.08
- David Roife · 1 shared paper, 2020 · strength 0.08
- Huamin Wang · 1 shared paper, 2020 · strength 0.08
- Ya’an Kang · 1 shared paper, 2020 · strength 0.08
- Laura R. Prakash · 1 shared paper, 2020 · strength 0.08
- Paul J. Chiao · 1 shared paper, 2020 · strength 0.08
- Jason B. Fleming · 1 shared paper, 2020 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.